21087 ⎘
Medicinal preparations containing antigens or antibodies; Bacterial antigens; Enterobacteriales, e.g. Enterobacter Salmonella
Hydrogenase deficient bacterial strains
#302Immunizing compositions and methods of use
#303Bacterial delivery of biologically active polypeptides
#304Flagellin related polypeptides and uses thereof
#305ACTIVE IMMUNIZATION USING A SIDEROPHORE RECEPTOR PROTEIN
#306Composition and method for controlling intestinal pathogenic organisms
#307COMPOSITION AND METHOD FOR CONTROLLING INTESTINAL PATHOGENIC ORGANISMS
#308Preparation of Salmonella Broad-Spectrum Vaccines
#309Saccharide Conjugate Vaccines
#310Attenuated serovar paratyphi a and uses thereof
#311vaccine
#312Sustained release vaccine composition
#313Live Attenuated Salmonella For Use as Vaccine
#314bacteriophage and uses thereof
#315Protein matrix vaccines and methods of making and administering such vaccines
#316Salmonella vaccine
#317Fusion proteins comprising flagellin and dengue viral envelope proteins
#318Attenuated FNR Deficient Enterobacteria
#319Conjugation of biomolecules using Diels-Alder cycloaddition
#320Live Attenuated Bacterial Vaccine
#321IRIDOID GLYCOSIDE COMPOSITION
#322Trehalose producing cells as vaccines
#323Immune response stimulating composition comprising nanoparticles based on a methyl vinyl ether-maleic acid copolymer
#324Inactivating organisms using carbon dioxide at or near its supercritical pressure and temperature conditions
#325Cloning and expression of outer membrane protein C of salmonella typhi Ty2 and conjugation of the purified insoluble protein to VI-polysaccharide for use as a vaccine for typhoid fever
#326Method of immunizing humans against using a Vi-EPA conjugate vaccine
#327Polysaccharide-protein conjugate vaccines
#328Live Attenuated Samonella Strains for Producing Monovalent or Multivalent Vaccines
#329Non-toxic mutants of pathogenic gram-negative bacteria
#330Orally-administered live bacterial vaccines for plague
#331Cloning and expression of outer membrane protein C of Salmonella typhi Ty2 and conjugation of the purified insoluble protein to VI-polysaccharide for use as a vaccine for typhoid fever
#332Non-toxic mutants of pathogenic gram-negative bacteria
#333Immunotherapy based on dendritic cells
#334Genetically modified tumor-targeted bacteria with reduced virulence
#335Regulated attenuation of live vaccines to enhance cross-protective immunogenicity
#336Immunogenic compositions comprising
#337Methods for reducing fecal shedding
#338Method of obatining cochlear structures, vaccine compositions, adjuvants and interme- diates thereof
#339Plasmid maintenance system for antigen delivery
#340Plasmid maintenance system for antigen delivery
#341Plasmid maintenance system for antigen delivery
#342Active immunization using a siderophore receptor protein
#343Intranasal recombinant Salmonella vaccine encoding heterologous polysaccharide antigens
#344Genetically modified tumor-targeted bacteria with reduced virulence
#345Compositions produced using enteric pathogens and methods of use
#346Live attenuated salmonella strains for producing monovalent or multivalent vaccines
#347Immunogenic compositions and methods of use thereof
#348polypeptides and methods of use
#349Non-toxic mutants of pathogenic gram-negative bacteria
#350Plasmid maintenance system for antigen delivery
#351Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
#352Method for the production of a verified enriched shell egg